Subtopic Deep Dive
Medical Management of Uterine Fibroids
Research Guide
What is Medical Management of Uterine Fibroids?
Medical management of uterine fibroids uses pharmacological agents like GnRH agonists, selective progesterone receptor modulators, and ulipristal acetate to control symptoms such as heavy bleeding and reduce fibroid volume while preserving fertility.
Research centers on ulipristal acetate, which controlled excessive bleeding and shrank fibroids in 13 weeks (Donnez et al., 2012, 673 citations). Long-term ulipristal acetate treatment sustains these effects (Donnez et al., 2014, 330 citations). Progesterone drives fibroid growth, justifying receptor modulator therapies (Ishikawa et al., 2010, 351 citations). Over 20 papers detail these approaches.
Why It Matters
Ulipristal acetate offers preoperative symptom control, avoiding immediate surgery for 70% of reproductive-age women with fibroids (Donnez et al., 2012; Giuliani et al., 2020). It preserves fertility unlike hysterectomy, addressing demand for non-surgical options amid rising diagnoses (Vilos et al., 2015). Long-term use reduces recurrence, improving quality of life (Donnez et al., 2014). Progesterone-targeted therapies counter fibroid dependence on ovarian steroids (Ishikawa et al., 2010).
Key Research Challenges
Ulipristal Liver Toxicity
Ulipristal acetate risks rare liver injury, prompting treatment pauses (Donnez et al., 2012; Donnez et al., 2014). Monitoring protocols remain inconsistent across trials. Balancing efficacy against hepatotoxicity needs refined guidelines (Giuliani et al., 2020).
Fertility Impact Uncertainty
Medical therapies shrink fibroids but fertility outcomes post-treatment vary (Taylor and Gomel, 2007). Progesterone modulators may impair endometrial receptivity (Ishikawa et al., 2010). Long-term data on conception rates post-ulipristal is limited (Vilos et al., 2015).
Side Effect Management
GnRH agonists cause hypoestrogenic symptoms like hot flashes, limiting duration (Khan et al., 2014). Selective progesterone modulators induce amenorrhea with spotting risks (Donnez et al., 2014). Optimizing regimens to minimize adverse effects while controlling bleeding persists as a gap (Giuliani et al., 2020).
Essential Papers
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Jacques Donnez, Т. Ф Татарчук, Philippe Bouchard et al. · 2012 · New England Journal of Medicine · 673 citations
Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. (Funded by PregLem; ClinicalTrials.gov number,...
The Management of Uterine Leiomyomas
George A. Vilos, Catherine Allaire, Philippe Y. Laberge et al. · 2015 · Journal of Obstetrics and Gynaecology Canada · 611 citations
Epidemiology and management of uterine fibroids
Emma Giuliani, Sawsan As‐Sanie, Erica E. Marsh · 2020 · International Journal of Gynecology & Obstetrics · 603 citations
Abstract Uterine leiomyomas are one of the most common and yet understudied diseases in women. These tumors, commonly known as fibroids, affect women mainly during their reproductive years and are ...
Physiology of the Endometrium and Regulation of Menstruation
Hilary Critchley, Jacqueline A. Maybin, Gregory M Armstrong et al. · 2020 · Physiological Reviews · 474 citations
The physiological functions of the uterine endometrium (uterine lining) are preparation for implantation, maintenance of pregnancy if implantation occurs, and menstruation in the absence of pregnan...
Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications
Pamela Stratton, K. J. Berkley · 2010 · Human Reproduction Update · 419 citations
Major advances in improving understanding and alleviating pain in endometriosis will likely occur if the focus changes from lesions to pain. In turn, how endometriosis affects the CNS would be best...
Uterine fibroids: current perspectives
Aamir Hameed Khan, Manjeet Shehmar, Janesh Gupta · 2014 · International Journal of Women s Health · 393 citations
Uterine fibroids are a major cause of morbidity in women of a reproductive age (and sometimes even after menopause). There are several factors that are attributed to underlie the development and in...
The uterus and fertility
Elizabeth Taylor, Victor Gomel · 2007 · Fertility and Sterility · 371 citations
Reading Guide
Foundational Papers
Start with Donnez et al. (2012, 673 citations) for ulipristal efficacy RCT; Ishikawa et al. (2010, 351 citations) for progesterone mechanisms; Khan et al. (2014, 393 citations) for morbidity overview.
Recent Advances
Giuliani et al. (2020, 603 citations) on epidemiology; Vilos et al. (2015, 611 citations) on management guidelines; Donnez et al. (2014, 330 citations) for long-term ulipristal.
Core Methods
Ulipristal acetate (selective progesterone modulator) induces amenorrhea and shrinks fibroids via receptor antagonism (Donnez et al., 2012). GnRH agonists suppress estrogen; add-back therapy mitigates side effects (Vilos et al., 2015).
How PapersFlow Helps You Research Medical Management of Uterine Fibroids
Discover & Search
Research Agent uses searchPapers and exaSearch to find ulipristal trials like 'Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery' (Donnez et al., 2012). citationGraph reveals 673 citations linking to Donnez et al., 2014 extensions. findSimilarPapers uncovers progesterone modulator studies from Ishikawa et al., 2010.
Analyze & Verify
Analysis Agent applies readPaperContent to extract bleeding reduction metrics from Donnez et al., 2012, then runPythonAnalysis with pandas to compute effect sizes across trials. verifyResponse (CoVe) checks claims against GRADE grading for high-quality RCTs. Statistical verification confirms fibroid volume reductions (p<0.001).
Synthesize & Write
Synthesis Agent detects gaps in long-term fertility data post-ulipristal, flagging contradictions between symptom control and pregnancy outcomes. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Donnez et al., 2012/2014; latexCompile generates polished manuscripts. exportMermaid visualizes treatment comparison flowcharts.
Use Cases
"Compare bleeding reduction stats across ulipristal acetate RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Donnez et al., 2012 data) → matplotlib plot of effect sizes output.
"Draft review on ulipristal for fibroid symptom management"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Vilos et al., 2015) → latexCompile → PDF with cited flowchart via exportMermaid.
"Find analysis code for fibroid volume measurements"
Research Agent → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox tests ultrasound quantification scripts linked to Giuliani et al., 2020.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (250M+ via OpenAlex) → citationGraph on Donnez et al., 2012 → structured report with GRADE scores. DeepScan applies 7-step analysis with CoVe checkpoints to verify ulipristal efficacy claims from 10+ papers. Theorizer generates hypotheses on progesterone resistance from Ishikawa et al., 2010 literature.
Frequently Asked Questions
What defines medical management of uterine fibroids?
It involves drugs like ulipristal acetate and GnRH agonists to shrink fibroids and control heavy bleeding without surgery (Donnez et al., 2012).
What are key methods in this subtopic?
Ulipristal acetate for 13-week cycles reduces bleeding and fibroid size; long-term intermittent use sustains effects (Donnez et al., 2012; Donnez et al., 2014).
What are key papers?
Donnez et al. (2012, 673 citations) shows ulipristal superiority over placebo; Vilos et al. (2015, 611 citations) guidelines management; Ishikawa et al. (2010, 351 citations) proves progesterone essentiality.
What open problems exist?
Liver safety with prolonged ulipristal, fertility preservation post-therapy, and optimal agonist-addback regimens lack consensus (Donnez et al., 2014; Giuliani et al., 2020).
Research Uterine Myomas and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Medical Management of Uterine Fibroids with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Uterine Myomas and Treatments Research Guide